Response to post-axitinib treatment in patients with metastatic renal cell carcinoma

被引：0

作者：

Namita Chittoria

Housam Haddad

Paul Elson

Nizar M. Tannir

Laura S. Wood

Robert Dreicer

Jorge A. Garcia

Brian I. Rini

Eric Jonasch

机构：

[1] Cleveland Clinic Taussig Cancer Center,

[2] University of Texas M. D. Anderson Cancer Center,undefined

[3] University of Virginia,undefined

[4] Veteran Affairs Medical Center,undefined

来源：

BMC Cancer | / 16卷

关键词：

Renal cell carcinoma; Axitinib; Sunitinib; VEGF inhibitors; mTOR inhibitors; Predictive biomarkers;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 13 条

[1]

Linehan WM(2010)The genetic basis of kidney cancer: a metabolic disease Nat Rev Urol 7 277-85

[2]

Srinivasan R(2011)Hallmarks of cancer: the next generation Cell 144 646-74

[3]

Schmidt LS(2011)Tilting the AXIS towards therapeutic limits in renal cancer Lancet 378 1898-900

[4]

Hanahan D(2009)Sequential therapy with sorafenib and sunitinib in renal cell carcinoma Cancer 115 61-7

[5]

Weinberg RA(2008)Signaling inhibitors in metastatic renal cell carcinoma Cancer J 14 325-9

[6]

Bex A(undefined)undefined undefined undefined undefined-undefined

[7]

Haanen J(undefined)undefined undefined undefined undefined-undefined

[8]

Dudek AZ(undefined)undefined undefined undefined undefined-undefined

[9]

Zolnierek J(undefined)undefined undefined undefined undefined-undefined

[10]

Dham A(undefined)undefined undefined undefined undefined-undefined